EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Angiopoietin-2 aggravates Alzheimer’s disease by promoting blood-brain barrier dysfunction and neuroinflammation

Eunhyeong Lee, Seoyeon Kim, Claire L Zhu, Erica Acquarone, Sungsoo Kim, An Lo, Omar M F Omar, Maraake Taddese, Viviana Gradinaru, Patrick A Murphy, Dritan Agalliu, Ottavio Arancio und 2 weitere

Cell Reports · 2026-01 · 45 (1) · 116621

DOI: 10.1016/j.celrep.2025.116621 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2026-01. Verfasst von Eunhyeong Lee und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Cell Biology, Columbia University, New York, NY, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Blood-Brain Barrier, Angiopoietin-2, Neuroinflammatory Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, Melanoma Research Alliance.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disruption of the blood-brain barrier (BBB) increases vascular permeability and promotes neuroinflammation, contributing to Alzheimer's disease (AD) progression. However, the molecular drivers of BBB dysfunction and neuroinflammation in AD remain poorly defined. Here, we identify angiopoietin-2 (ANGPT2) as a central mediator of BBB breakdown and AD progression. Transcriptomic analyses of human AD brains revealed elevated ANGPT2 expression in endothelial cells correlating with disease severity. In 5xFAD mice, endothelial-specific Angpt2 deletion reduced β-amyloid deposition, while Angpt2 overexpression via an adeno-associated viral vector exacerbated the plaque burden. Mechanistically, ANGPT2 suppression of TIE2 signaling increased vascular leakage and fibrin deposition, triggering microglial activation and neuroinflammatory responses that accelerated disease progression. Single-nucleus transcriptomic analyses further revealed Angpt2-driven microglial dysfunction and neuronal impairment consistent with memory deficits observed in behavioral assays. These findings establish ANGPT2 as a critical driver of BBB dysfunction and neuroinflammation in AD and highlight its therapeutic potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseBlood-Brain BarrierAngiopoietin-2Neuroinflammatory DiseasesAnimalsHumansMiceReceptor, TIE-2MicrogliaAmyloid beta-PeptidesEndothelial CellsMaleMice, TransgenicInflammation

Stichwörter der Autor:innen

Alzheimer’s diseaseCP: neuroscienceangiopoietin-2blood-brain barrier dysfunctionneuroinflammationsnRNA-seqspatial memoryβ-amyloid

Substanzen

Angiopoietin-2Receptor, TIE-2Amyloid beta-Peptides

Autor:innen und Institutionen

  • Department of Pathology and Cell Biology, Columbia University, New York, NY, USA.
  • Department of Integrated Biomedical and Life Science, Korea University, Seoul, Republic of Korea; L-HOPE Program for Community-Based Total Learning Health Systems, Korea University, Seoul, Republic of Korea.
  • Department of Pathology and Cell Biology, Columbia University, New York, NY, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, USA.
  • Center for Vascular Biology, University of Connecticut Medical School, Farmington, CT, USA.
  • Division of Biology & Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
  • Department of Pathology and Cell Biology, Columbia University, New York, NY, USA; Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA.

Förderung

  • NIA NIH HHS
  • NINDS NIH HHS
  • Melanoma Research Alliance
  • National Institute on Aging
  • American Cancer Society Inc
  • National Institutes of Health National Cancer Institute
  • National Institute of Neurological Disorders and Stroke
  • Herbert Irving Comprehensive Cancer Center, Columbia University

Zitieren

APA

Lee, E., Kim, S., Zhu, C. L., Acquarone, E., Kim, S., Lo, A., Omar, O. M. F., Taddese, M., Gradinaru, V., Murphy, P. A., Agalliu, D., Arancio, O., An, J. Y., & Kim, M. (2026). Angiopoietin-2 aggravates Alzheimer’s disease by promoting blood-brain barrier dysfunction and neuroinflammation. Cell Reports, 45(1), 116621. https://doi.org/10.1016/j.celrep.2025.116621

Vancouver

Lee E, Kim S, Zhu CL, Acquarone E, Kim S, Lo A, et al. Angiopoietin-2 aggravates Alzheimer’s disease by promoting blood-brain barrier dysfunction and neuroinflammation. Cell Reports. 2026;45(1):116621. doi:10.1016/j.celrep.2025.116621

BibTeX
@article{Lee2026,
  author = {Lee, Eunhyeong and Kim, Seoyeon and Zhu, Claire L and Acquarone, Erica and Kim, Sungsoo and Lo, An and Omar, Omar M F and Taddese, Maraake and Gradinaru, Viviana and Murphy, Patrick A and Agalliu, Dritan and Arancio, Ottavio and An, Joon-Yong and Kim, Minah},
  title = {Angiopoietin-2 aggravates Alzheimer’s disease by promoting blood-brain barrier dysfunction and neuroinflammation},
  journal = {Cell Reports},
  year = {2026},
  volume = {45},
  number = {1},
  pages = {116621},
  doi = {10.1016/j.celrep.2025.116621}
}
Kostenlos starten →